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Background: Sleep quality and genetics may contribute to the etiology of gastrointestinal (GI) symptoms.
Individuals with impaired sleep often have a number of associated symptoms including chronic abdominal pain
(CAP). The current study examined the interactions of brain-derived neurotrophic factor (BDNF) genotype with sleep
quality in persons with CAP and healthy controls. In addition, associations among sleep quality, BDNF genotype,
and gene expression were explored in the participants.
Methods: Data were collected on 59 participants (46% male, 61% White, 26.9 ± 6.6 years; CAP (n=19) and healthy
controls (n=40)). Participants with CAP reported poorer sleep quality compared to healthy controls. BDNF genotype,
categorized as Val/Val homozygotes versus the Met carriers.
Results: Microarray analysis found twenty-four differentially expressed genes by a two-fold magnitude in participants
with poor sleep quality compared to good sleep quality, and seven differentially expressed genes comparing CAP to
healthy control. Three specific genes in the pain group overlap with sleep quality, including insulin-like growth factor 1
(IGF1), spermatogenesis associated serine-rich 2-like (SPATS2L), and immunoglobulin heavy constant gamma 1 or mu
(IGHG1/// IGHM). BDNF was shown to have an interaction effect with GI and sleep symptoms.
Conclusions: Participants with CAP reported poor sleep quality compared to healthy controls. The role of the BDNF
Met allele on differential gene expression was not distinct as main factor, but impacted interactions with sleep quality
and CAP. Down-regulation of IGF1, SPATS2L, and IGHG1 expression may be related to the etiology of poor sleep quality
and CAP.
Trial registration: Clinicaltrial.gov # NCT00824941
Keywords: Sleep, Gene expression, BDNF, Chronic abdominal painBackground
Chronic abdominal pain (CAP) affects an estimated 15 −
20% of people worldwide [1,2], and is a symptom common
to functional gastrointestinal (GI) disorders [3-5] such as
irritable bowel syndrome (IBS). GI disorders are estimated
to cost the United States approximately $30 billion
annually related to lost productivity and medical care [6-8].* Correspondence: hendersw@mail.nih.gov
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unless otherwise stated.Sleep is necessary to health and well-being and, too little or
too much sleep may increase the risk of developing chronic
conditions [9,10]. Sleep disturbances are also associated
with increased IBS symptoms [11-14]. In subjects with IBS,
sleep scores are significantly correlated with pain [14].
There is evidence that genetics predispose people to
alterations in sleep architecture and pain [9,10,15,16]. Brain-
derived neurotrophic factor (BDNF) is encoded by the
BDNF gene, which contains a single nucleotide polymorph-
ism (SNP) Val66Met (rs6265), where adenine and guanine
alleles vary, resulting in a variation of valine to methionine
at codon 66. Studies by Bachmann et al. [16] show that
BDNF Val66Met polymorphism modulates sleep intensityLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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the study found pronounced variations in slow wave sleep
activity specific to BDNF. Another study indicated that
elevated BDNF expression in IBS patients compared to
healthy controls is correlated with higher abdominal pain
scores [17]. Although there are limited studies involving IBS
and BDNF, a 10-biomarker index that included BDNF, was
used to differentiate IBS from non-IBS subjects and found
to be sensitive and specific [18].
The purpose of this study was twofold: (a) to compare
sleep quality between participants with CAP and healthy
controls and (b) to explore interactions among sleep qual-
ity, BDNF alleles, and gene expression in participants with
CAP and healthy controls. It was expected that findings
would provide new insights into the role of gene expression
in relation to sleep quality and chronic pain conditions.
Methods
Design and setting
The study was approved by the Institutional Review Board
and the Office of Human Subjects Research at the NIH.
Participants were exclusively recruited to a natural history
protocol (09-NR-0064, Clinicaltrial.gov # NCT00824941)
conducted at the Hatfield Clinical Research Center, NIH.
Details on participant’s recruitment, inclusion and exclusion
criteria are provided in Additional file 1. Participants gave
written consent and questionnaires were collected for sleep
measurements during outpatient visits from January 2009
to July 2011. The peripheral blood samples were collected
from fasting participants during the same visit.
Sample demographics and clinical variables
Demographics and clinical characteristics, and the sleep





Females 32 (54%) 14
Males 27 (46%) 5
Race (n)
Black 10 (17%) 3
Asian 10 (17%) 2
White 36 (61%) 13
Mixed 3 (5%) 1
Age 26.93 ± 6.64 26
Range (yrs) (13–45) (1
Body Mass Index (BMI) 25.34 ± 5.26 25
Range (kg/m2) (18.65 - 43.22) (2
Age and BMI values are reported as mean ± standard deviation.Healthy controls met the inclusion criteria for age, menses
(females) and had no history of abdominal pain. Also,
healthy controls had no other organic disorders or GI dis-
eases (e.g., inflammatory bowel disease, celiac disease, bil-
iary disorders, bowel resection) and had no cardiac,
pulmonary, neurologic, renal, endocrine, or gynecological
pathology and had no other exclusions (see Additional
file 1). CAP is defined as a self-reported history of greater
than 6 months of abdominal pain of unknown origin and
no known diagnosed organic cause for the abdominal
pain. This information is determined by self-report and
confirmed by medical record review.
Gender, race, and age (in years) were collected using
the Socio-demographic Questionnaire developed by the
Center for Research in Chronic Disorders, University of
Pittsburgh School of Nursing (1999) and administered
through the Clinical Trials Database. During the clinical
visit, the participant’s weight was measured in triplicate
and height was measured in duplicate. The average
height and weight were used to determine body mass
index (BMI), calculated as weight in kilograms divided
by height in meters squared (Table 1).
Sleep measurement
Participants rated their sleep quality by using the PSQI
[19] questionnaire, which provides a subjective measure
of sleep quality over the past month. The questionnaire
contains 19 self-reported questions and 5 questions
completed by a bed partner. The latter 5 questions are
used for clinical information only, not tabulated in the
scoring of the PSQI. The 19 self-reported questions are
grouped into seven component scores: 1) sleep latency,
2) sleep disturbances, 3) daytime dysfunction, 4) medica-
tions to sleep, 5) overall sleep quality, 6) duration ofhy controls and participants with chronic abdominal pain
P Healthy control p-value









.68 ± 4.77 27.05 ± 7.42 0.821
4–33) (13–45)
.31 ± 4.49 25.35 ± 5.64 0.974
0.19 - 35.07) (18.65 - 43.22)
Table 2 Sleep quality measures of healthy controls and participants with chronic abdominal pain (CAP)
PSQI measures Total CAP Healthy control p-value
(n=59) (n=19) (n= 40)
Global PSQI score 4.63 ± 0.41 6.42 ± 0.80 3.78 ± 0.40 0.006*
Sleep latency 0.98 ± 0.12 1.42 ± 0.21 0.78 ± 0.14 0.014*
Sleep disturbances 1.10 ± 0.07 1.32 ± 0.13 1.00 ± 0.07 0.046*
Daytime dysfunction 0.69 ± 0.10 1.16 ± 0.21 0.48 ± 0.10 0.006*
Medications to sleep 0.19 ± 0.08 0.47 ± 0.22 0.05 ± 0.05 0.077
Overall sleep quality 0.92 ± 0.09 1.11 ± 0.15 0.83 ± 0.10 0.131
Duration of sleep 0.39 ± 0.09 0.47 ± 0.18 0.35 ± 0.11 0.558
Sleep efficiency 0.36 ± 0.11 0.47 ± 0.23 0.30 ± 0.11 0.507
PSQI: Pittsburgh Sleep Quality Index.
Data are reported as mean ± standard deviation; *Significant findings (p-value ≤0.05).
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scores were summed to obtain a global PSQI score,
ranging from 0–21 (Table 2). Component scores range
from 0 (good sleep quality) to 3 (poor sleep quality).
Global PSQI score ≤5 is associated with good sleep
quality and >5 with poor sleep quality [19]. Buysse and
colleagues reported internal consistency reliability for
the PSQI for overall component and individual item
scores (Cronbach’s α=0.83). Global PSQI scores >5 were
reported to have a sensitivity of 89.6% and specificity of
86.5% in comparing poor sleepers to good sleepers [19].
DNA extraction and BDNF genotyping
Peripheral blood was collected from the participants
using a yellow top BD Vacutainer® (BD Biosciences,
Franklin Lakes, NJ) and frozen immediately at −80°C
until the time of extraction. DNA extraction was per-
formed on 5 mL of blood using the QIAamp DNA
Blood Maxi Kit (Qiagen, Frederick, MD) according to
the manufacturer’s instructions. If less than 5 mL of
blood was available, phosphate buffered saline was added
to bring the total volume to 5 mL. DNA concentration
was determined by NanoDrop™ 1000 spectrophotometer
(Thermo Scientific, Wilmington, DE) and, extracted
DNA was stored at −20°C prior to genotyping assay.
Sample DNA was dried overnight on a MicroAmp™ op-
tical 384-Well reaction plate (in duplicates) at a concentra-
tion 5 ng/μL. Per genotyping protocol of the manufacturer,
Assay ID: C_11592758_10 (product # 4351379), DNA was
subsequently combined with the TaqMan® Universal PCR
Master Mix and TaqMan® SNP Genotyping Assay Mix
(Applied Biosystems, Foster City, CA). The genotyping
assay contains two unlabeled primers (forward and
reverse) for amplifying the sequence of interest and two
labeled probes for detecting alleles. The probes consist
of target-specific oligonucleotides with a reporter dye at
the 5′- end of each probe, VIC® dye (linked to the 5′-
end of the allele 1 probe), 6FAM™ dye (linked to the 5′-
end of the allele 2 probe). Also, the probes incorporatenonfluorescent quencher on 3′-end attached to a minor
groove binder.
Allelic discrimination PCR reactions (40 cycles) were
then performed for BDNF rs6265 on 7900 HT Fast Real-
Time PCR System (Applied Biosystems, Foster City, CA).
Subsequently, an endpoint fluorescence measurement was
obtained with the Sequence Detection Systems (SDS) soft-
ware of 7900 HT Fast system (Applied Biosystems, Foster
City, CA), to examine the samples for discrimination
between the specific alleles.
RNA isolation and amplification
The blood samples (2.5 mL) from each participant were
collected in PAXgene (Qiagen, Valencia, CA) tubes and
stored at −81°C. Total RNA was extracted and purified
from each blood sample using a RNA PAXgene kit
(Qiagen, Frederick, MD) according to the manufacture’s
protocol and stored at −81°C. The RNA quality and quan-
tity were determined by spectrometry and by using the
RNA 6000 Nano LabChip kit on a 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA). Total RNA that
passed quality control criteria was used for microarray
and qPCR experiments.
Microarray processing
Microarrays were processed by one person at the Labora-
tory of Molecular Technology, National Cancer Institute
(NIH, Frederick, MD), following standard operating
protocol to minimize non-biologic technical bias. The
RNA quantity, purity, and integrity were assessed by a
NanoDrop™ 1000 spectrophotometer (Wilmington, DE)
and Experion electrophoresis station (Bio-Rad Laboratories,
Hercules, CA), respectively, or by 2100 Bioanalyzer using
the RNA 6000 Nano LabChip kit (Agilent Technologies,
Santa Clara, CA). All samples had a high quality score
(RIN >9).
Double-stranded cDNA, was synthesized from 10 ng
total RNA followed by a linear isothermal amplification to
produce single-strand cDNA, which was direct labeled by
Table 3 BDNF genotyping (N= 49 participants) and the
clinical measures of pain and sleep quality
ID BDNF Pain Sleep quality
3 Val/Val Healthy Control Poor quality
6 Val/Val Healthy Control Good quality
7 Val/Val Healthy Control Good quality
11 Val/Val CAP Good quality
12 Val/Val Healthy Control Poor quality
14 Val/Val Healthy Control Good quality
16 Val/Val CAP Poor quality
17 Val/Val Healthy Control Good quality
18 Val/Val Healthy Control Poor quality
20 Val/Val Healthy Control Poor quality
22 Val/Val Healthy Control Good quality
25 Val/Val Healthy Control Good quality
26 Val/Val Healthy Control Good quality
28 Val/Val Healthy Control Poor quality
31 Val/Val Healthy Control Good quality
35 Val/Val Healthy Control Good quality
36 Val/Val Healthy Control Good quality
38 Val/Val CAP Poor quality
39 Val/Val Healthy Control Good quality
40 Val/Val Healthy Control Good quality
41 Val/Val CAP Poor quality
42 Val/Val CAP Good quality
44 Val/Val CAP Good quality
46 Val/Val CAP Good quality
49 Val/Val Healthy Control Good quality
51 Val/Val Healthy Control Good quality
52 Val/Val Healthy Control Good quality
55 Val/Val CAP Good quality
57 Val/Val Healthy Control Good quality
61 Val/Val CAP Poor quality
64 Val/Val CAP Poor quality
65 Val/Val CAP Good quality
66 Val/Val CAP Good quality
69 Val/Val CAP Poor quality
1 Met Carrier Healthy Control Good quality
2 Met Carrier Healthy Control Poor quality
8 Met Carrier Healthy Control Good quality
15 Met Carrier Healthy Control Good quality
24 Met Carrier Healthy Control Good quality
27 Met Carrier CAP Good quality
29 Met Carrier Healthy Control Good quality
32 Met Carrier CAP Poor quality
33 Met Carrier Healthy Control Good quality
Table 3 BDNF genotyping (N= 49 participants) and the
clinical measures of pain and sleep quality (Continued)
34 Met Carrier Healthy Control Poor quality
37 Met Carrier Healthy Control Good quality
43 Met Carrier CAP Poor quality
45 Met Carrier CAP Poor quality
53 Met Carrier CAP Poor quality
56 Met Carrier Healthy Control Good quality
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technologies, Inc., San Carlos, CA) following manufac-
turer’s protocol. Biotinylated cDNA (4.4 μg) from each
sample was mixed with the control buffer and hybridized
on each Human Genome U133 plus 2.0 array (Affymetrix,
Santa Clara, CA) at 45°C for 16 hours in a GeneChipTable 4 Sample cohort (N= 26) for microarray
experiments comprising BDNF genotype and the clinical
measures of pain and sleep quality
ID BDNF Pain Sleep quality
3 Val/Val Healthy Control Poor quality
6 Val/Val Healthy Control Good quality
11 Val/Val CAP Good quality
16 Val/Val CAP Poor quality
22 Val/Val Healthy Control Good quality
25 Val/Val Healthy Control Good quality
35 Val/Val Healthy Control Good quality
36 Val/Val Healthy Control Good quality
38 Val/Val CAP Poor quality
39 Val/Val Healthy Control Good quality
40 Val/Val Healthy Control Good quality
41 Val/Val CAP Poor quality
44 Val/Val CAP Good quality
46 Val/Val CAP Good quality
49 Val/Val Healthy Control Good quality
52 Val/Val Healthy Control Good quality
55 Val/Val CAP Good quality
8 Met Carrier Healthy Control Good quality
24 Met Carrier Healthy Control Good quality
27 Met Carrier CAP Good quality
29 Met Carrier Healthy Control Good quality
32 Met Carrier CAP Poor quality
37 Met Carrier Healthy Control Good quality
43 Met Carrier CAP Poor quality
45 Met Carrier CAP Poor quality
56 Met Carrier Healthy Control Good quality
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washed on Fluidics Station 450 using manufacturer’s
recommended scripts and scanned on GeneChip Scanner
3000 (Affymetrix, Santa Clara, CA). GeneChip Command
Console (AGCC 3.0, Affymetrix) was used to scan the
images and for data acquisition.
To enable the comparison between arrays, a global scal-
ing factor (target signal to 500) was used across all arrays to
minimize the variables caused by sample preparation,
hybridization/ staining or from different lots of arrays.
Microarray quality control was evaluated for each array
by examination of background, noise, average signal, %
present, ratio of signal values for probe sets representing
the 5′ and 3′ ends of actin and glyceraldehyde-3-phosphateTable 5 Microarray differentially expressed genes for the slee
(>2.0 and< −2.0) criteria (subset of 26 participants)
Probeset ID Gene symbol Gene title
232011_s_at MAP1LC3A microtubule-associated
chain 3 alpha
1555019_at CDHR1 cadherin-related family
230537_at --- ---
209541_at IGF1 insulin-like growth factor
223595_at TMEM133 transmembrane protein
229116_at CNKSR2 connector enhancer of
Ras 2
203830_at C17orf75 chromosome 17 open r
223275_at PRMT6 protein arginine methyl
218875_s_at FBXO5 F-box protein 5
225153_at GFM1 G elongation factor, mit
1556096_s_at UNC13C unc-13 homolog C (C. e
219443_at TASP1 taspase, threonine aspar
211647_x_at IGHG1 /// IGHM immunoglobulin heavy
(G1m marker) /// immu
constant mu
1552972_at LOC100507431 uncharacterized LOC100
215617_at SPATS2L spermatogenesis associa
225114_at AGPS alkylglycerone phospha
213929_at EXPH5 exophilin 5
206557_at ZNF702P zinc finger protein 702,
201689_s_at TPD52 tumor protein D52
211635_x_at IGHA1 /// IGHA2 /// IGHD ///





209891_at SPC25 SPC25, NDC80 kinetoch
component, homolog (S
211634_x_at IGHM immunoglobulin heavy
214973_x_at IGHD immunoglobulin heavy
FDR: False Discovery Rate.dehydrogenase transcripts, and total signal for probesets for
BioB, BioC, BioD and CreX.
qPCR experiments
Total RNA (200 ng) was reverse transcribed using the
RT2 First Strand cDNA Synthesis Kit (Qiagen, Frederick,
MD). RT2 PCR Primer Assays and RT2 SYBR Green
PCR Master Mix (Qiagen, Frederick, MD) were used to
analyze trends in the gene expression of IGF-1, IGHG1,
and SPATS2L. These genes were significantly expressed
comparing CAP to healthy control, and also comparing
poor quality sleep to good sleep quality. All reactions
were plated in triplicate and beta actin (known as
ACTB) was used as a housekeeping gene. The PCR platep quality group that passed FDR (5%) and fold change
p-value sleep quality
(poor sleep vs. good
sleep)
Fold-change sleep
quality (poor sleep vs.
good sleep)
protein 1 light 2.39E-05 2.3261
member 1 2.59E-05 2.1365
4.27E-05 −2.0029
1 (somatomedin C) 8.64E-06 −2.0056
133 4.85E-07 −2.0090
kinase suppressor of 4.74E-05 −2.0228
eading frame 75 2.21E-05 −2.0231
transferase 6 4.54E-05 −2.0384
2.39E-05 −2.1082
ochondrial 1 1.06E-05 −2.1148
legans) 3.98E-05 −2.1205





ted, serine-rich 2-like 1.23E-05 −2.3091










constant mu 4.61E-05 −3.1417
constant delta 6.75E-05 −4.6680
Table 6 Microarray differentially expressed genes for the pain group that passed FDR (5%) and fold change (>2.0
and< −2.0) criteria (subset of 26 participants)
Probeset ID Gene symbol Gene title p-value pain (CAP vs.
healthy control)
Fold-change pain (CAP vs.
healthy control)
*215617_at SPATS2L spermatogenesis associated, serine-rich 2-like 4.28E-06 2.5283
*230537_at --- --- 3.41E-06 2.3876
*233398_at --- --- 3.95E-06 2.3134
*209541_at IGF1 insulin-like growth factor 1 (somatomedin C) 2.55E-06 2.1813
236062_at --- --- 2.52E-06 2.1507
*211647_x_at IGHG1 /// IGHM ///
LOC100133862
immunoglobulin heavy constant gamma 1 (G1m
marker) /// immunoglobulin heavy constant mu
2.81E-06 2.1102
1565874_at --- --- 2.22E-06 2.02869
FDR: False Discovery Rate.
*Probesets (genes) of pain group overlap with Sleep quality group.
Gene List_Sleep quality
(poor sleep vs. good sleep)
24
Gene List_Pain
(CAP vs. Healthy Control)
7
209541_at: IGF1






Figure 1 Intersection of two lists of significant genes. Venn
diagram showing the overlap of most differentially expressed genes
of the sleep quality (poor sleep vs. good sleep, total of 24) and pain
groups (CAP vs. healthy control, total of 7). The gene names and
probeset IDs are provided for the pain group, and also that overlap
with the sleep quality group. Although 5 genes overlap, gene
names are available for three: IGF1, SPATS2L, and IGHG1///IGHM.
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run on 7900 HT real-time cycler (Applied Biosystems,
Foster City, CA).
Data analysis
Descriptive statistics for all demographic, clinical vari-
ables and sleep quality measures were calculated using
SPSS Statistics (IBM SPSS Inc., Chicago, IL) (Tables 1
and 2). Comparisons were made for age and BMI be-
tween the two levels of pain group (CAP versus healthy
control) of the participants using t-tests. For sleep
quality measures, a priori p-values <0.05 were considered
significant (Table 2).
For the analysis of genotyping data, the threshold for
Quality value, which influences the allele call was set to
100 (Additional file 2: Table S1). Chi-square tests were
performed to study the associations of BDNF SNP with
categorical measures of sleep quality (poor sleep versus
good sleep) and pain groups (CAP versus healthy control).
The BDNF Met allele has previously been associated and
implicated in various behavioral and cognitive processes
[20-22]. In order to assess the associations of the Met
allele with the sleep, pain and gene expression data,
heterozygous and homozygous Met genotypes were
grouped together into a Met carrier group (Table 3) for
comparison with the homozygous Val genotype (or
non-Met carrier group) as is typically done in the study
of these alleles due to the low frequency of the homozy-
gous Met genotype [20,22].
Microarray data on 26 participants (a subset of 59 sam-
ple full cohort, Table 4 and Additional file 2: Table S2)
were analyzed for gene expression patterns using Partek
Genomics Suite software (Partek Inc., St. Louis, MO). The
probe-level robust multichip average background correc-
tion, quantile normalization and Log2 transformation
followed by probe-set summarization were performed on
gene expression intensity values. Multi-way ANOVA was
used to compare the gene expression profiles between the
two levels of, Pain: CAP (11) and healthy control (15),Sleep quality: poor sleep quality (7) and good sleep quality
(19) and BDNF: Val homozygous (17) and Met carriers (9).
Gender (Females 15 and Males 11) was included in the
analysis. The interaction terms of sleep quality * pain,
sleep quality * BDNF, and pain * BDNF were included in
the 4-way ANOVA model. Differentially expressed gene
lists were generated for sleep quality and pain groups by a
magnitude of 2-fold change (in either direction), and
at the false discovery rate (FDR) 0.05 level. The same
fold change criteria was used to obtain differentially
expressed genes for BDNF groups, but with unadjusted
p-values <0.05 as FDR criteria were not fulfilled.
Interactive pathway analysis (Qiagen Systems, Redwood
City, CA) was performed on differentially expressed genes
between poor sleep quality and good sleep quality to
Reddy et al. BMC Medical Genomics 2014, 7:61 Page 7 of 12
http://www.biomedcentral.com/1755-8794/7/61identify gene networks associated with specific bio-
logical functions. Genes were colored based on expression
values, up-regulated in red and down-regulated in green,
respectively. Connectivity of differentially expressed genesFigure 2 Expression patterns of IGF1, SPATS2L, and IGHG1 /// IGHM for
quality and pain groups of the differentially expressed gene: (a) IGF1, (b) SPAT
least square mean of the gene expression intensity. The samples are colored bwas made via the molecules added from Ingenuity know-
ledge database. A network was generated based on signifi-
cant differentially expressed genes of CAP compared to
healthy control.sleep and pain groups. Distribution of the intensity values for sleep
S2L and, (c) IGHG1 /// IGHM. The y-axis represents the log2 normalized
y sleep quality (good sleep in red and poor sleep in blue).
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were uploaded and analyzed with the use of Web Analysis
tool (http://www.sabiosciences.com/). Threshold cycle
cut-off was set at 35 cycles per literature recommenda-
tion and trends in gene expression were analyzed in
respect to a 95% confidence interval.Figure 3 Sources of variation of the significant genes. Effect of various
(a) IGF1, (b) SPATS2L, and (c) IGHG1 /// IGHM. Factors of ANOVA model an
of variance) of the gene on the y-axis. Average mean square values for eacResults and discussion
The sample comprised 59 participants (46% male, 61%
White, 26.9 ± 6.6 years), which included individuals with
CAP (n=19) and healthy controls (n=40) (Table 1). A com-
parison of age and body mass index (BMI) showed no sig-
nificant differences between CAP and healthy controlsfactors and the interactions across the differentially expressed genes:
d random error are on the x-axis and mean squared F Ratio (measure
h factor and interaction are provided.
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are given in Table 2. As expected, participants with CAP
had significantly higher scores than healthy controls on
the global Pittsburgh Sleep Quality Index (PSQI), sleep la-
tency, sleep disturbances, and daytime dysfunction scores.
Higher sleep scores on the PSQI scale equate to poorer
sleep quality. Also, there was a trend toward higher scores
for medications to sleep and overall sleep quality in partic-
ipants with CAP compared to healthy controls (Table 2).
However, there were no significant differences in measures
of duration of sleep or sleep efficiency between the two
groups. These results are consistent with studies reported
in literature on relationships between sleep quality and
IBS [14,23,24].
Genotyping studies were employed to explore BDNF
SNP (rs6265) on the sleep quality (poor sleep versus good
sleep) and pain (CAP versus healthy control) groups. The
raw data from genotyping experiment processed on 59Figure 4 Functional network associated with the differentially expres
differential expression of sleep quality group (good sleep versus poor sleep
are shown), down-regulation in green and, up-regulation in red. Genes wit
Direct and indirect relationships are shown by solid and dashed lines, respe
Gene associations with some of the digestive system development functiosamples is given in Additional file 2: Table S1. The Quality
value reflects the probability of the genotype call or Val66-
Met polymorphism. Data were dichotomized as the
homozygous Val group (i.e., Val/Val; GG alleles) and Met
carriers consisting of genotypes supporting the Met allele
(i.e., Val/Met (GA alleles) and Met/Met (AA alleles).
Depending on the detection of SNPs, data on 49 samples
were used for analysis, given in Table 3. There were no
significant associations observed with regard to BDNF
SNP with sleep quality or pain grouping.
Details of the cases and healthy controls of the sample
cohort used for microarray experiments are given in Table 4.
Also, the demographics of the microarray sample cohort
are provided in Additional file 2: Table S2. There were no
significant differences between the microarray cohort and
the full cohort with regard to gender, age, or BMI. The dis-
tribution of BDNF genotypes are known to vary among
races [25-28]. Our study included a substantial Caucasiansed genes. Schematic diagram of a gene network related to
). Coloring of genes is based on differential expression (fold changes
h no coloring are added from Ingenuity knowledge database.
ctively. The arrow indicates specific directionality of interactions.
ns are shown.
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an analysis of both SNP and gene expression data while
controlling for the possible effects of race.
Gene expression studies by microarray showed majority
of differentially expressed genes comparing poor sleep
quality to good sleep quality group were down-regulated
(by a two-fold magnitude, Table 5). Interestingly, for the
pain group, the CAP had increased gene expression (>2.0
fold) compared to healthy controls (Table 6). Three specific
named genes overlap in the sleep quality (poor sleep versus
good sleep) and pain (CAP versus healthy control) groups:
insulin-like growth factor 1 (IGF1), spermatogenesis asso-
ciated, serine-rich 2-like (SPATS2L), and immunoglobulin
heavy constant gamma 1 or mu (IGHG1//IGHM). Also,
two unnamed genes (probesets 230537_at and 233398_at)
overlap between sleep quality and pain groups (Figure 1).
The intensity of specific genes such as IGF1, SPATS2L,
and IGHG1 /// IGHM are shown across the two groups
of pain and sleep quality (Figure 2). An examination of
gene expression profiles associated with CAP showed
decreased values for poor sleep quality compared to
good sleep quality. In healthy controls, the difference in
gene expression was minimal based on sleep quality for
IGF1 and SPATS2L genes (Figures 2a and 2b).
Differentially expressed genes for BDNF group, compar-
ing Val homozygous to Met carriers are given in Additional
file 2: Table S3. The most prominent down-regulated genes
are human leukocyte antigen, major histocompatibility
complex, class II, DQ alpha 1(HLA-DQA1) and urotensionFigure 5 Molecular paths and interactions of the significant genes. Sp
generated from Ingenuity knowledge database related to gastrointestinal d
(CAP vs. healthy control). Direct and indirect relationships are shown by so2 (UTS2). HLA-DQA1 plays an important role in immune
system and is expressed in antigen presenting cells. Varia-
tions of HLA-DQA1 gene have been associated with an
increased risk of celiac disease. UTS2, a neuropeptide
expressed only in brain tissue, is implicated in regulation
of sleep stages [29]. Differentially expressed genes of
BDNF groups are found to have no overlap with differen-
tially expressed genes of either pain group or sleep quality
group. An examination of the main factors (BDNF, sleep
quality, and pain) and their interactions on differential
gene expression of IGF1, SPATS2L, and IGHG1/// IGHM
(Figure 3) indicates that BDNF has an indirect effect,
which is additive to the model.
Real time PCR was used to validate the microarray
results. Participants with CAP had up-regulation in the
expression of IGF1, IGHG1 and SPATS2L (2.83-fold,
1.36-fold and 1.05-fold respectively) compared to healthy
controls. The three genes showed fold change by a factor
of 0.252, 0.735, and 0.950 for IGF1, IGHG1 and SPATS2L,
respectively (95% CI: 0.00001, 2.64; 0.00001, 5.18; 0.00001,
6.42).
Interactive pathway analysis (IPA) (Qiagen Ingenuity
Systems, Inc., Redwood City, CA) on differential expressed
genes comparing poor sleep quality to good sleep quality
resulted in a network associated with functions such as
cellular development, hematopoiesis, and tissue morph-
ology. A schematic diagram of functional gene network is
shown in Figure 4, of which some have a role in gas-
trointestinal diseases. Differentially expressed genes areecific interactions for the genes IGF1, IGHM, and SPATS2L were
iseases. Red coloring indicates up-regulated genes for the pain group
lid and dashed lines, respectively. Potential biomarkers are shown.
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http://www.biomedcentral.com/1755-8794/7/61colored (up-regulated in red and down-regulated in
green). The genes uncolored are absent in the differentially
expressed gene list, but have relationships as shown in the
network. The growth factor IGF1 appears pivotal, involved
with the proliferation of intestinal cell lines and gastric
epithelial cells (Figure 4).
Molecular paths generated based on the most significant
genes of pain group, IGF1, SPATS2L, and IGHM are
shown in Figure 5. SPATS2L is a gene of unknown func-
tion, involved in protein-protein interactions, binding to
Ubiquitin (UBC) protein (Figures 4), and regulated by D-
glucose [30]. SPATS2L, along with IGF1, have a direct
interaction with a nuclear receptor, hepatocyte nuclear
factor 4 alpha (HNF4A) and an indirect interaction with
D-glucose (Figure 5). Mutant LOC26010 (SPATS2L) gene
with SNP substitution, allelic variation: A/G (rs2881745)
was shown to be associated with arthritis in humans [31].
Another significant gene, IGHM is a trans-membrane re-
ceptor and has an important role in B cell development
and signaling [32]. IGHM has a direct interaction with
amyloid-β precursor protein (APP), the latter in indirect
interaction with IGF1 (Figures 4 and 5).
Of the 3 genes of interest, more has been published on
the relationship between IGF1 and sleep [33-35]. Growth
hormone is important, because reductions in this neuro-
peptide are associated with increased sleep latency, as
well as increases in wakening, and reduced duration of
sleep [34]. Decreased levels of serum IGF1 are associated
with excessive daytime sleepiness [33], and sleep apnea
[34,35] in patients compared to healthy controls.
A growing number of studies show subclinical inflam-
mation in IBS, therefore potentially relating to similar
findings of a reduction of serum IGF1 in inflammatory
bowel diseases [36,37]. The results of our study are rele-
vant in that IGF1 is an important initiator of cellular
repair processes, induces intestinal and linear growth,
and may be linked to chronic inflammatory gastro-
intestinal pathway [38,39]. Also, IGF1 was shown to have
a protective effect against inflammation in the bowel
[40] and found to be therapeutic in patients with inflam-
matory bowel disease [40-42].
Conclusions
Participants with CAP reported poor sleep quality com-
pared to healthy controls. The role of the BDNF Met allele
as main effect on gene expression is not obvious although
sleep and pain have an influence on differential gene
expression. However, the interactions of Met allele with
sleep quality or pain impacts differential gene expression.
Poor sleep quality in those with CAP may be related to the
down-regulation of IGF1, SPATS2L, and IGHG1. A larger
sample size with balanced study designs in future studies is
needed to better delineate the relationships between BDNF
and sleep quality or BDNF and pain. Future researchtargeting the associations of sleep quality in participants
with co-morbid GI conditions is imperative.
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